Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Shares in cell-targeted therapeutic products developer CepTor Corporation have seen an increase after the company announced that new compound patents are pending for NeuroDur in multiple sclerosis.
Subscribe to our email newsletter
Intellectual property filings have been made to further strengthen the company’s patent position for its nerve cell targeted protease inhibitor platform technology. More specifically, CepTor has filed to receive an additional 20 years of compound protection for oral delivery of Neurodur with accompanied use protection in multiple sclerosis (MS) and other neurodegenerative diseases.
“Protecting our property remains a never-ending priority,” stated William Pursley, CepTor’s chairman and CEO. “We are unaware of any other specific nerve cell targeted, protease inhibiting compounds being used or developed to minimize or prevent the degradation of nerve tissue associated with MS and other neurodegenerative diseases.”
“We believe specific targeting provides us the unique benefit of potentially delivering our therapeutic compounds more safely and, in terms of efficacy, more efficiently,” he continued.